Unfortunately, data show the 340B program has lost its way. Taxpayers are footing part of the bill but not seeing any benefits in terms of improved access to affordable medicines.
The U.S. biopharma and med-tech industries are adding their voice to that of Gilead Sciences Inc. in urging the California Supreme Court to review the Gilead Tenofovir Cases, which seek to hold the drug company liable for how and when it developed its pipeline of HIV drugs.
(Reuters) -A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs. U.S. District Judge David Ezra in Austin, Texas, sided with President Joe Biden's administration in dismissing a lawsuit by the Pharmaceutical Research and Manufacturers of America (PhRMA) and two other groups that argued the program was unconstitutional. "We are disappointed with the court's decision, which does not address the merits of our lawsuit, and we are weighing our next legal steps," Nicole Longo, a PhRMA spokesperson, said in a statement.
Steve Tilton will return to the Pharmaceutical Research and Manufacturers of America (PhRMA) as senior vice president of federal advocacy. He succeeds Anne Esposito, who stepped down this summer after 3 1/2 years in the role. The influential industry group is regrouping after the passage of the Inflation Reduction Act, which included provisions to slash…